Pre-Open 01/10: (SRNE) (SNX) (DERM) Higher (PTLA) (SIX) (SPWH) Lower (more...)
- Nasdaq ends at record high as Big Tech roars back
- Sanderson Farms (SAFM) Explores Sale - Report
- Bitcoin (BTC) Cracks $30,000 to Hit 6-Month Low, Here Are Next Targets Lower
- Dollar lower as Powell reaffirms pledge to not raise rates too quickly
- Splunk (SPLK) Lands $1 Billion From Silver Lake, Announces Buyback One Day After Activist Rumors Surface
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Today's Pre-Open Stock Movers
Sorrento Therapeutics, Inc. (NASDAQ: SRNE) 49.9% HIGHER; announced today that on January 9, 2020, it received a non-binding proposal from a private equity fund to acquire a majority or all of the issued and outstanding shares of the Company for up to $7.00 per share.
Portola Pharmaceuticals, Inc. (Nasdaq: PTLA) 40.9% LOWER; For the fourth quarter, the Company expects Andexxa global net revenues to be approximately $28 million. For the full year 2019, the Company expects Andexxa global net revenues to be approximately $111 million. (*** consensus is $134 million)
Six Flags Entertainment (NYSE: SIX) 17.5% LOWER; Disclosing Challenges in China Development
Sportsmans Warehouse (Nasdaq: SPWH) 16.4% LOWER; For the fourth quarter of fiscal year 2019, net sales are now expected to be in the range of $250 million to $254 million based on same stores sales in the range of down 7.0% to down 6.0% compared to the corresponding period of fiscal year 2018. Adjusted net income is now expected to be in the range of $7.5 million to $9.3 million with adjusted earnings per diluted share now expected to be in the range of $0.17 to $0.21 on a weighted average of approximately 43.5 million common shares outstanding. (*Consensus sees Q4 EPS of $0.32 on revenue of $267.9 million)
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) 14.5% HIGHER; announced positive results from ATI-450-PKPD-101, a Single Ascending Dose and Multiple Ascending Dose (SAD/MAD) Phase 1 clinical trial of the investigational compound ATI-450. Preliminary data demonstrated that ATI-450:
Moderna, Inc., (Nasdaq: MRNA) 12.9% HIGHER; announced positive seven-month interim safety and immunogenicity data after the third and final vaccination in the Phase 1 study of its investigational cytomegalovirus (CMV) vaccine (mRNA-1647). The findings build on the previously reported three-month interim analysis, after two vaccinations, announced at the Companys R&D Day in September 2019. Additionally, the Company announced that the first participant was dosed in the Phase 2 dose-confirmation study. mRNA-1647 is a wholly owned program in Modernas prophylactic vaccines portfolio.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) 10.2% HIGHER; announced topline positive safety and efficacy data from Cohort 3 and longer-term data from Cohort 2 of the ongoing Phase 1/2 study of DTX301, an investigational adeno-associated virus (AAV) gene therapy for the treatment of ornithine transcarbamylase (OTC) deficiency. In Cohort 3 (n=3), there were two confirmed female responders as well a third potential male responder who requires longer-term follow-up to confirm response status. In Cohort 2, one female patient has newly demonstrated a response starting at Week 52 which was confirmed at Week 78. The two previously disclosed responders in Cohort 1 and Cohort 2 also remain clinically and metabolically stable at 104 and 78 weeks, respectively. Across all nine patients dosed in the study, up to six patients have demonstrated a response.
Matinas BioPharma Holdings, Inc. (NYSE: MTNB) 10% LOWER; announced that it has commenced an underwritten public offering of its common stock.
Urban Outfitters, Inc. (NASDAQ: URBN) 9.5% LOWER; holiday comparable Retail segment net sales increased 3%, driven by growth in the digital channel, partially offset by negative retail store sales.
SYNNEX Corporation (NYSE: SNX) 9.5% HIGHER; plan to separate into two publicly traded companies: comprising of SYNNEX Technology Solutions, a leading IT distribution, services and integrated solutions company, and Concentrix, a leading global CX solutions company. Immediately following the transaction, SYNNEX shareholders will own shares of both SYNNEX and Concentrix.
Grubhub (NYSE: GRUB) 9% HIGHER; confirmed in a statement to StreetInsider.com that there are no plans to sell the company, countering reports earlier in the week from the Wall Street Journal that the company was exploring a sale.
Kadmon Holdings (NYSE: KDMN) 8% HIGHER; Nomura/Instinet initiates coverage on with a Buy rating and a price target of $10.00.
T2 Biosystems, Inc. (NASDAQ: TTOO) 7.9% HIGHER; Fourth quarter total revenue of approximately $3.0 million, an increase of 67% compared to the prior year period.
Aptinyx Inc. (Nasdaq: APTX) 6.9% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering.
WD-40 Co. (NASDAQ: WDFC) 5.1% LOWER; reported Q1 EPS of $0.88, $0.10 worse than the analyst estimate of $0.98. Revenue for the quarter came in at $98.6 million versus the consensus estimate of $103.97 million. WD-40 Co. sees FY2020 EPS of $4.74-$4.83, versus the consensus of $4.79.
VOXX Int'l (NASDAQ: VOXX) 5% LOWER; reported Q3 EPS of $0.10, versus $0.50 reported last year. Revenue for the quarter came in at $110.1 million versus the consensus estimate of $129.64 million.
Simulations Plus (NASDAQ: SLP) 4.2% HIGHER; reported Q4 EPS of $0.11, $0.01 better than the analyst estimate of $0.10. Revenue for the quarter came in at $9.4 million versus the consensus estimate of $8.61 million.
Dermira, Inc. (NASDAQ: DERM) 3.6% HIGHER; Eli Lilly and Company (NYSE: LLY) and Dermira, Inc. (NASDAQ: DERM) today announced a definitive agreement for Lilly to acquire Dermira for $18.75 per share, or approximately $1.1 billion, in an all-cash transaction. Dermira is a biopharmaceutical company dedicated to developing new therapies for chronic skin conditions.
KB Home (NYSE: KBH) 3.6% LOWER; reported Q4 EPS of $1.31, $0.02 better than the analyst estimate of $1.29. Revenue for the quarter came in at $1.56 billion versus the consensus estimate of $1.61 billion.
Intuitive (Nasdaq: ISRG) 2.9% HIGHER; Fourth quarter 2019 worldwide da Vinci procedures increased approximately 19% compared with the fourth quarter of 2018. Full year 2019 worldwide da Vinci procedures increased approximately 18% compared with 2018. Preliminary fourth quarter 2019 revenue of $1.278 billion grew 22% compared with $1.047 billion for the fourth quarter of 2018. Preliminary 2019 revenue of $4.479 billion grew 20% compared with $3.724 billion for 2018.
Appian Corp. (NASDAQ: APPN) 2.4% HIGHER; Needham & Company initiates coverage on with a Buy rating and a price target of $49.00.
II-VI, Inc. (NASDAQ: IIVI) 2% LOWER; Raymond James downgraded from Outperform to Market Perform.
NVIDIA (NASDAQ: NVDA) 1.7% HIGHER; BofA Securities raised the price target on to a 'Street High' $300.00
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Best Solar Stocks to Invest in 2021? Wall Street Weighs In
- Nicolet Bankshares (NCBS) To Acquire County Bancorp (ICBK)
- Sally Beauty (SBH) Gains After Being Upgraded at Both Cowen and Oppenheimer to 'Outperform' as Recent Pullback Creates Attractive Entry Point
Create E-mail Alert Related CategoriesSpecial Reports
Related EntitiesRaymond James, Needham & Company, Nomura, Earnings, Pre-Open Losers, Pre-Open Winners, Definitive Agreement, Pre Market Movers
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!